Based on previous reports describing the synergistic effects of CUDC-907 in various cancer models and since PI3K signaling also plays an eminent role for CRPC development (see the aforementioned role of mTOR inhibitors), CUDC-907 was investigated in prostate cancer models. The gene discussed is MTOR; the disease is prostate cancer.